ABBV did not explicitly change its prior guidance for $1.7B of 2022 Mavyret sales. Given the 1Q22 sales of $380M, quarterly Mavyret sales will have to average $440M for the next three quarters in order to meet the $1.7B figure. This is doable if—and only if—new-patient starts return to pre-pandemic levels.
Market Data 
Markets 
AI
